Journal
BIOMEDICINES
Volume 10, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines10020341
Keywords
metabolism; mitochondria; pulmonary hypertension
Categories
Funding
- National Key Research and Development Program of China [2019YFE0119400]
- Natural Science Foundation of China [81970052, 81770059, 82170057, 82000055]
- National Institutes of Health [P01HL134610, P01HL146369]
Ask authors/readers for more resources
This review focuses on the alterations in mitochondrial metabolism that occur in deranged pulmonary vessels and the right ventricle in pulmonary arterial hypertension (PAH), including abnormalities in glycolysis and glucose oxidation, fatty acid oxidation, glutaminolysis, redox homeostasis, as well as iron and calcium metabolism. Further understanding of these mitochondrial metabolic mechanisms could provide viable therapeutic approaches for PAH patients.
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary arterial pressure due to increased pulmonary vascular resistance, secondary to sustained pulmonary vasoconstriction and excessive obliterative pulmonary vascular remodeling. Work over the last decade has led to the identification of a critical role for metabolic reprogramming in the PAH pathogenesis. It is becoming clear that in addition to its role in ATP generation, the mitochondrion is an important organelle that regulates complex and integrative metabolic- and signal transduction pathways. This review focuses on mitochondrial metabolism alterations that occur in deranged pulmonary vessels and the right ventricle, including abnormalities in glycolysis and glucose oxidation, fatty acid oxidation, glutaminolysis, redox homeostasis, as well as iron and calcium metabolism. Further understanding of these mitochondrial metabolic mechanisms could provide viable therapeutic approaches for PAH patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available